IntroMedic (KOSDAQ:A150840) - Share price, News & Analysis

A150840 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

A150840 Stock Overview

IntroMedic Co., Ltd. develops and supplies medical equipment in South Korea and internationally.

Risk Analysis

Earnings have declined by 16.6% per year over past 5 years

Shares are highly illiquid

Shareholders have been diluted in the past year

IntroMedic Competitors

Price History & Performance

Summary of all time highs, changes and price drops for IntroMedic
Historical stock prices
Current Share Price	₩5,850.00
52 Week High	₩8,220.00
52 Week Low	₩2,200.00
Beta	0.37
1 Month Change	0%
3 Month Change	2.99%
1 Year Change	151.61%
3 Year Change	-6.85%
5 Year Change	62.73%
Change since IPO	105.26%

Recent News & Updates

Mar 11

IntroMedic's (KOSDAQ:150840) Stock Price Has Reduced 68% In The Past Three Years

This week we saw the IntroMedic Co., Ltd. ( KOSDAQ:150840 ) share price climb by 13%. But over the last three years...

Shareholder Returns

	A150840	KR Medical Equipment	KR Market
7D	0%	-0.9%	-0.2%
1Y	151.6%	-6.6%	-15.5%

Return vs Industry: A150840 exceeded the KR Medical Equipment industry which returned -6.6% over the past year.

Return vs Market: A150840 exceeded the KR Market which returned -15.5% over the past year.

Price Volatility

Is A150840's price volatile compared to industry and market?
A150840 volatility
A150840 Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	5.9%
Market Average Movement	5.6%
10% most volatile stocks in KR Market	10.4%
10% least volatile stocks in KR Market	3.2%

Stable Share Price: Insufficient data to determine A150840's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine A150840's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2004	60	Yong Seok Cho	https://www.intromedic.com

IntroMedic Co., Ltd. develops and supplies medical equipment in South Korea and internationally. It offers MiroCam, a capsule endoscope system; E.G. Scan, a disposable ductile esophagoscope; and EndoClot, an absorbent hemostasis equipment.

IntroMedic Fundamentals Summary

How do IntroMedic's earnings and revenue compare to its market cap?
A150840 fundamental statistics
Market Cap	₩223.67b
Earnings (TTM)	-₩13.74b
Revenue (TTM)	₩7.87b

28.4x

P/S Ratio

-16.3x

P/E Ratio

Is A150840 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
A150840 income statement (TTM)
Revenue	₩7.87b
Cost of Revenue	₩3.39b
Gross Profit	₩4.48b
Other Expenses	₩18.22b
Earnings	-₩13.74b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-359.42
Gross Margin	56.95%
Net Profit Margin	-174.60%
Debt/Equity Ratio	15.1%

How did A150840 perform over the long term?

See historical performance and comparison

Valuation

Is IntroMedic undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

4.33x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate A150840's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A150840's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: A150840 is unprofitable, so we can't compare its PE Ratio to the KR Medical Equipment industry average.

PE vs Market: A150840 is unprofitable, so we can't compare its PE Ratio to the KR market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate A150840's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: A150840 is overvalued based on its PB Ratio (4.3x) compared to the KR Medical Equipment industry average (2.4x).

Future Growth

How is IntroMedic forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

5.7%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as IntroMedic has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has IntroMedic performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-16.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A150840 is currently unprofitable.

Growing Profit Margin: A150840 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: A150840 is unprofitable, and losses have increased over the past 5 years at a rate of 16.6% per year.

Accelerating Growth: Unable to compare A150840's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A150840 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (30.5%).

Return on Equity

High ROE: A150840 has a negative Return on Equity (-26.86%), as it is currently unprofitable.

Financial Health

How is IntroMedic's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: A150840's short term assets (₩37.0B) exceed its short term liabilities (₩11.0B).

Long Term Liabilities: A150840's short term assets (₩37.0B) exceed its long term liabilities (₩1.7B).

Debt to Equity History and Analysis

Debt Level: A150840's net debt to equity ratio (5.2%) is considered satisfactory.

Reducing Debt: A150840's debt to equity ratio has reduced from 64.5% to 15.1% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: A150840 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: A150840 has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 10.1% each year.

Dividend

What is IntroMedic current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate A150840's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A150840's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A150840's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A150840's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A150840 has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

CEO

Yong Seok Cho

no data

Tenure

Yong Seok Cho is Chief Executive Officer and President of IntroMedic Co., Ltd.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.7%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/20 00:00
End of Day Share Price	2022/03/14 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31